Wed, Jul 23, 2014, 12:41 AM EDT - U.S. Markets open in 8 hrs 49 mins

Recent

% | $
Click the to save as a favorite.

ACI Worldwide, Inc. Message Board

ybajerk2007 20 posts  |  Last Activity: Jul 17, 2014 9:27 AM Member since: Jul 23, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • ybajerk2007 by ybajerk2007 Jul 17, 2014 9:27 AM Flag

    Two week delay in releasing LymPro data has created a buying opportunity.

    Down from .178 to under .13.

    Chairman's blog expected today or tomorrow.

    Twitter: @AmarantusBio .... 10,000+ followers.

  • ybajerk2007 by ybajerk2007 Jul 10, 2014 11:17 AM Flag

    Most undervalued micro-cap biotech in the market. A dozen pennies currently.

    Launching first blood test to detect Alzheimer's this year. Major news expected at the A.A.I.C. next week.

    Due diligence. Start be reading the recent Yahoo news.

    Twitter: @AmarantusBio .... 9,972 followers.

  • Don't get burned when the bottom falls out.

  • Reply to

    Finalizing LymPro Partnership

    by ambsadvocate May 29, 2014 12:10 PM
    ybajerk2007 ybajerk2007 May 30, 2014 11:00 AM Flag

    .50 is possible this year.

  • ybajerk2007 by ybajerk2007 May 30, 2014 10:54 AM Flag

    Dr. Joseph Rubinfeld, one of the co-founders of Amgen, is on the company's advisory board.

    Due diligence.

    Launching the first blood test to detect early stage Alzheimer's this year.

    Twitter: @AmarantusBio .... 9,971 followers.

    Buy a few shares under a dime.

  • ybajerk2007 by ybajerk2007 May 30, 2014 10:47 AM Flag

    Due diligence.

    Buy under a dime.

    Thank me in six weeks.

  • ybajerk2007 by ybajerk2007 May 30, 2014 10:32 AM Flag

    Under a dime.

    Listen to yesterday's Marcum MicroCap Presentation:

    wswDOTcom/webcast/marcum2/ambs/

    Launching diagnostic test to detect early stage Alzheimer's.

    Twitter: @AmarantusBio .... 9,971 followers.

    Zacks: Buy Rating

  • ybajerk2007 ybajerk2007 Apr 26, 2014 9:13 AM Flag

    Daviscupper is a very "sick" individual. Ignore him.

    Everything is Gone!
    by daviscupper • Mar 31, 2014 6:59 PM

    My account, that is. The nightmare scenario unfolded. Huge margin calls due to my prior large sale of puts that I had to buy to close for a huge amount and had to sell ALL of my PRAN shares at a 70% loss to cover those options. Total wipeout (above 600K). Totally ruined. Have a few 1000 bucks left in the account. it has not been fun today. I will never speculate heavily on one biotech stock ever again. I haven not told my wife yet, I don't know if I can face her. I had refinanced my house because I thought this was such a sure thing. What should I do know? Please only serious responses!!!

  • ybajerk2007 by ybajerk2007 Mar 27, 2014 11:46 AM Flag

    "AMBS"

    Bottom is in today at .07.

    Zack's analyst Jason Napadano says it's a buy with a .24 price target.

    Read the recent Yahoo news.

    Twitter: @AmarantusBio ... 9,672 followers.

  • ybajerk2007 by ybajerk2007 Mar 27, 2014 11:44 AM Flag

    Bottom is in today at .07.

    Zack's analyst Jason Napadano says it's a buy with a .24 price target.

    Read the recent Yahoo news.

    Twitter: @AmarantusBio ... 9,672 followers.

  • ybajerk2007 by ybajerk2007 Sep 11, 2013 2:40 PM Flag

    Buy a few shares under seven cents today. Becton Dickinson/LymPro news due out at any time.

    Second "orphan indication" for the company's MANF drug is rumored to be in the field of diabetes. Novartis and Novo Nordisk are possible parties of interest.

    Due diligence.

    Follow the company on Twitter: @AmarantusBio .... 8,467 followers

  • ybajerk2007 by ybajerk2007 Sep 10, 2013 9:12 AM Flag

    "AMBS" - Most undervalued bio-tech. Buy a few shares under a dime. Read the recent Yahoo news.

    Presenting today at the Rodman & Renshaw Investor's Conference. Visit the company's website to obtain the link.

    Follow the company on Twitter: @AmarantusBio .... 8,460 followers

  • ybajerk2007 ybajerk2007 Sep 10, 2013 9:01 AM Flag

    Assessment applies any morning. :-)

  • ybajerk2007 by ybajerk2007 Sep 10, 2013 8:58 AM Flag

    Presenting at the Rodman & Renshaw Investor's Conference today. Substantially undervalued.

    Follow on Twitter: @AmarabtusBio 8,459 followers

    300% upside short term.

  • Reply to

    Something To Consider

    by wcoastguy2008 Aug 27, 2013 9:13 AM
    ybajerk2007 ybajerk2007 Sep 10, 2013 8:55 AM Flag

    Presenting at the Rodman & Renshaw Investor's Conference today.

    Jason Napadano says its current value is four times the current share price.

    Due diligence.

  • ybajerk2007 by ybajerk2007 Sep 5, 2013 12:44 PM Flag

    Company announced new financing yesterday and the share price took a hit to below six cents.

    The company now has operating capital for the next 18 months.

    An anticipated deal with Becton Dickinson will move the share price above .50.

    The company's patented MANF drug could also be worth billions of dollars.

    Follow the company on Twitter: @AmarantusBio 8,430 followers

  • "AMBS" - Most undervalued micro cap biotech in the market. Currently trading under a dime.

    Read the recent Yahoo news.

    License deal with Becton Dickinson is in the works.

  • ybajerk2007 by ybajerk2007 Aug 12, 2013 1:46 PM Flag

    "AMBS" - Currently trading under a nickle.

    SUNNYVALE, Calif., Aug. 12, 2013 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced positive data for MANF in the degenerative disease known as Retinitis Pigmentosa ("RP"). The study concluded that Intravitreal injection of recombinant human MANF protein protects both rods and cones from retinal degeneration in an animal model of RP. RP is a degenerative disorder of the eye that affects roughly 100,000 people in the United States, meaning that it qualifies as an orphan disease under FDA guidelines.

    RP refers to a group of inherited diseases causing retinal degeneration. The cell-rich retina lines the back inside wall of the eye and is responsible for capturing images from the visual field. People with RP experience a gradual decline in their vision because photoreceptor cells (rods and cones) die. Symptoms include a progressive degeneration of peripheral and night vision as well as the degeneration in color perception and central vision; night blindness is one of the earliest and most frequent symptoms of RP. RP is typically diagnosed in adolescents and young adults. The rate of progression and degree of visual loss varies from person to person. Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.

    "The data announced today is tremendously important to our MANF Orphan program," said Gerald E. Commissiong, CEO of Amarantus. "As we continue to move our internal MANF programs forward related to mediating endoplasmic reticulum (ER) stress, we can now expand the MANF therapeutic development franchise into Ophthalmology. By identifying Retinitis Pigmentosa as an indication for MANF, we have identified a potentially reduced timeline to get MANF to commercialization with a very substantial market opportunity."

  • "AMBS" - diagnostic test to detect early stage Alzheimer's.

    Currently trading under a nickle. Buyout in the .50 range.

  • "AMBS" - due diligence.

ACIW
18.11+0.32(+1.80%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.